Background. May 22nd marks the beginning of a Shigatoxin-producing Escherichia coli (STEC) O104:H4 outbreak in Northern Germany. By its end on 27 July, it had claimed 53 deaths among 2987 STEC and 855 confirmed haemolytic-uraemic syndrome (HUS) cases. Methods. To describe short-term effectiveness of best supportive care (BSC), therapeutic plasma exchange (TPE) and TPE with eculizumab (TPE-Ecu) in 631 patients with suspected HUS treated in 84 hospitals in Germany, Sweden and the Netherlands using the webbased registry of the DGfN (online since 27 May). Results. Of 631 entries, 491 fulfilled the definition of HUS (median age 46 years; 71% females). The median (interquartile range) hospital stay was 22 (14-31) days. Two hundred and eighty-one (57%) patients underwent dialysis and 114 (23%) mechanical ventilation. Fifty-seven patients received BSC, 241 TPE and 193 TPE-Ecu. Treatment strategy was dependent on disease severity (laboratory signs of haemolysis, thrombocytopenia, peak creatinine level, need for dialysis, neurological symptoms, frequency of seizures) which was lower in BSC than in TPE and TPE-Ecu patients. At study endpoint (hospital discharge or death), the median creatinine was lower in BSC [1.1 mg/dL (0.9-1.3)] than in TPE [1.2 mg/dL (1.0-1.5), P < 0.05] and TPE-Ecu [1.4 mg/dL (1.0-2.2), P < 0.001], while need for dialysis was not different between BSC (0.0%, n = 0), TPE (3.7%; n = 9) and TPE-Ecu (4.7%, n = 9). Seizures were absent in BSC and rare in TPE (0.4%; n = 1) and TPE-Ecu (2.6%; n = 5) patients. Total hospital mortality in HUS patients was 4.1% (n = 20) and did not differ significantly between the TPE and TPE-Ecu groups. Conclusions. Despite frequent renal impairment, advanced neurological disorders and severe respiratory failure, shortterm outcome was better than expected when compared with previous reports. Within the limitations of a retrospective registry analysis, our data do not support the notion of a short-term benefit of Ecu in comparison to TPE alone in the 
Introduction
In early May 2011, an outbreak of haemorrhagic colitis associated with haemolytic-uraemic syndrome (HUS) first developed in Hamburg but soon spread to Northern Germany and 15 other countries in Europe [1] . As of 27 July 2011, 2987 cases of Shiga-toxin-producing Escherichia coli (STEC) colitis (18 deaths) and 855 reported cases of HUS (35 deaths) had been reported to the Robert-Koch-Institute (RKI), Germany's national centre for communicable disease prevention and control [2] . Sprouts were identified as the most likely outbreak vehicle [3] . The outbreak-strain O104:H4 combined virulence factors of typical enteroaggregative and Shiga-toxin-producing E. coli [4, 5] , which may have contributed to the 24% occurrence rate of HUS, whereas in STEC-infected children, the HUS rate usually ranges between 2 and 16% [6, 7] . The increased virulence was also considered responsible for the high rate of seizures and coma leading to mechanical ventilation and intensive care unit treatment. The unexpected clinical severity prompted an urgent quest for therapeutic options and guidance; yet, evidence and recommendations for the treatment of STEC-HUS are based on case series and uncontrolled studies. Thus, the German Society of Nephrology (DGfN) published treatment suggestions on its homepage (www. dgfn.eu). These included best supportive care (BSC), the use of therapeutic plasma exchange (TPE) and the application of eculizumab (Ecu), a humanized anti-C5 monoclonal antibody that inhibits terminal complement activation, with reference to contraindications, dose and duration of Ecu treatment.
In 1999, Dundas et al. [8] published a paper on 22 adult HUS patients urging to establish a national registry in the case of a large STEC-HUS outbreak. On 27 May 2011, 5 days after the outbreak had been officially reported, the DGfN set up a web-based STEC-HUS registry, which was continuously updated in the following weeks [9] . Up to now, this registry presents the largest population of HUS patients and provides analysis of essential epidemiological and laboratory data, as well as clinical information from hospital admission to discharge. We compared the effectiveness of BSC, TPE and TPE combined with Ecu (TPE-Ecu) with regard to renal, neurological and survival outcome. To adjust imbalances in disease severity of treatment groups, statistical models using a propensity score-based method were applied.
Materials and methods

Data collection
The online data collection form was developed by the Hannover Medical School and the University Hospital Hamburg Eppendorf under the auspices of the DGfN [9] and approved by local ethic committees on 23 and 25 May, respectively. The link to the online data collection form was posted on the DGfN website and widely communicated through its mailing list. Based on feedback from participating physicians, the website was updated thrice. From 30 June onwards, the English version of the registry was online (www.ehec-register.de).
The online data form allowed entry of demographic data, clinical symptoms, time course of the acute illness, presence of EHEC in stool sample, laboratory parameters as well as main information of given treatment regimens. For TPE, date of first treatment, number of treatments and information on the use of steroids and anticoagulation were collected. For Ecu, the date of first administration, number of administrations and continuation of TPE after the start of Ecu were obtained.
Serum creatinine and dialysis requirement were used to assess renal involvement. The presence or absence of headache, confusion, blurred speech, personality changes, visual impairment, seizures and coma at the point of maximum neurological involvement were registered. Outcome variables included length of hospital stay, renal function (including the need for dialysis) and neurological symptoms at the primary endpoint as well as overall mortality. Details of the recruiting centres are provided in Supplementary Table S1 .
Case definition of HUS
Patients were eligible for further statistical analysis if at least two out of three findings were given to fulfil HUS criteria: (i) thrombocytopenia (<150 × 10 9 /L), (ii) microangiopathic haemolytic anaemia lactate dehydrogenase (LDH > 240 U/L and haemoglobin <12.0 g/dL), and (iii) acute kidney injury according to the AKIN definition [10] .
Statistical analysis
Prior to final analysis, all database entries were extensively reviewed. For the detection of potentially incorrect or implausible data entries, computer programs using regular expressions were engineered to reassess the diagnosis of HUS. For patients presenting HUS, a descriptive statistics with frequency and percentage analysis for categorical and median and inter-quartile range (IQR) for continuous variables was performed. Continuous variables were evaluated for normal distribution by the Shapiro-Wilk test and in dependence of distribution further analysed with the Welch two-sample t-test or Wilcoxon rank-sum test, respectively. Categorical variables were compared using Pearson's χ 2 test. To assess the additional effect of Ecu over TPE alone, a matched cohort analyses using a propensity score-based algorithm was performed [11] : first was to decide which covariates, measured at the baseline, should be included in the propensity score model. Therefore, we investigate the extent to which a covariate is confounding the treatment (Ecu) effect on outcome [12] . As a result, body weight, grade of neurologic symptoms and the need for dialysis revealed a significant difference between the TPE-Ecu and TPE groups and were therefore considered as appropriate baseline covariates. To estimate the likelihood receiving Ecu in addition to TPE, a logistic model with baseline information about given covariates was fitted. Ratio for matching Ecu-treated patients to TPE only was set to a 1-to-1 basis and size of calibre was adapted to achieve non-significance difference of covariates between the TPE-Ecu and TPE groups (default was set in the order of one-fifth of the standard deviation of the logit of the estimated propensity score) [12, 13] .
Statistical computation was performed with R-Project software version 2.10.1 for Linux using additional packages for propensity scorebased matching analysis. Two-sided P-values of <0.05 were considered statistically significant.
Results
Patient selection
A total of 631 entries into the registry were made by a total of 84 centres. Out of these 631, 10 double entries, 58 patients lacking baseline parameter and 72 patients who did not fulfil the RKI criteria for HUS were excluded ( Figure 1 ). The 491 patients fulfilling the HUS definition were selected for further analysis. Four hundred and seventy-three (96%) came from Germany, 17 from Sweden and 1 from the Netherlands.
Baseline characteristics
The median age in the total cohort was 46 (IQR, 31-62) years, 71% were females. Patients were admitted 3 (IQR, 1-6) days after symptom onset and remained hospitalized for a median of 26 (IQR, 18-35) days. Dialysis was required in 281 (57%) and mechanical ventilation in 114 (23%) patients. TPE was performed in 426 (87%) patients and additional administration of Ecu (TPE-Ecu) in 193 (39%) patients, whereas 57 (12%) received BSC only.
Comparison of baseline parameters
While the 57 patients in the BSC group showed comparable baseline parameters in terms of gender distribution, weight, height and frequency of gastrointestinal symptoms, they were significantly older [54. Table 1) .
Severity of illness
As shown in Table 1 , patients receiving BSC had the mildest laboratory signs of HUS. At the baseline, TPE and TPE-Ecu patients did not differ in their lowest platelet count, but during hospital stay, the TPE-Ecu group presented greater haemolytic activity than the TPE group with higher peak LDH (P < 0.001) and lower minimum haemoglobin levels (P < 0.001) ( Table 1) .
Neurological symptoms ranging from headaches to seizures or coma were observed in 69% of the patients.
Relative frequency of any neurological symptoms was low in the BSC (45%), moderate in the TPE (59%) and high in the TPE-Ecu (89%) group (Supplementary Figure S1 ). Haemodialysis was needed in 57% (n = 281) patients, ranging from 21% (n = 12) in BSC, 52% (n = 124) in TPE to 75% (n = 145) in TPE-Ecu patients (P < 0.001) ( Table 1) .
Treatments
Allocation to the three treatment groups was based on documentation of the use of TPE alone (TPE group) or Ecu in addition to TPE (TPE-Ecu group). All other patients were considered to be in the BSC group.
The majority of total HUS patients (87%) underwent TPE. The mean number of TPE sessions was 6.3 sessions per patient with no difference between the TPE and TPEEcu groups. Plasma exchange was started at Day 7 (IQR, 5-9) after symptom onset in the TPE and at Day 6 (IQR, 4-7) in the TPE-Ecu group (P < 0.01). Ecu was administered 5 (IQR, 3-6) days after the first TPE session, i.e. Day 11 after the onset of symptoms, with 73% (n = 140) of the patients receiving >4 weekly doses ( Figure 2 ). After the first dose of Ecu, 49% (n = 69) of those underwent at least one additional TPE, while 61% (n = 42) were substituted with an additional dose of Ecu after TPE.
The transfusion trigger was in line with the current transfusion guidelines [14] and ranged from a haemoglobin level of 6.2 g/dL in the TPE-Ecu over 6.4 g/dL in the TPE to 7.0 g/dL in the BSC group. Overall requirement of RBC-transfusion was given in 192 (39%) out of 481 patients (9% in BSC, 35% in TPE and 53% in TPEEcu; P < 0.001).
Mechanical ventilation was needed in 114 (23%) patients (14% in BSC, 16% in TPE and 35% in TPEEcu). During hospital stay, patients' neurological symptoms decreased from 69 to 12% and did not significantly differ at discharge. In particular, severe neurological disorders (seizures) were no longer present in the BSC and only 0.4% (n = 1) in TPE and 2.6% (n = 5) in the TPE-Ecu group. Renal replacement therapy was required in 57.2% of hospitalized patients. However, the overall dialysis rate at discharge was only 3.6% with no significant difference between the BSC (n = 0), TPE (n = 9, 3.7%) and TPE-Ecu (n = 9, 4.7%) groups. The median creatinine at discharge significantly differs with lowest in BSC [1.1 (0.9-1. Of 491 patients 4.1% (13 females/7 males) died during the hospital stay. Mortality was higher in BSC (10.6%, P < 0.05) when compared with TPE (3.7%) and TPE-Ecu (2.6%) patients. The majority of reported causes of death were intervention-related bleeding complications (n = 5), refusal of dialysis and/or limitation of care due to advance directives (n = 4), cerebral disorders (stroke, haemorrhage) (n = 4), pneumonia (n = 2) and multi-organ failure following sepsis (n = 2). Patients who died were significantly older [70 (61.0-75. Table 2 .
Despite severe neurological disorders and frequent requirement of dialysis and mechanical ventilation, the overall survival of the 491 STEC-HUS patients was 95.6%.
Fortunately, short-term renal and neurological recovery was better than expected given the severe clinical course.
Discussion
Clinical presentation
Clinical presentation, baseline characteristics and mortality of registry patients are consistent with data from the RKI [15] . Activity of HUS and rate of dialysis were comparable to previous reports [8, [16] [17] [18] . Despite considerable improvement in renal function, the long-term sequelae remain to be determined as acute kidney injury increases the risk for chronic kidney disease [19] .
In our cohort, at least one of the seven defined clusters of neurological symptoms (headaches, confusion, speech abnormalities, personality changes, impaired vision, seizures and coma) occurred in 69% of the patients. In contrast to the classical text book definition, occurrence of neurological complications in HUS is associated with high mortality [20] . Interestingly, <2% had persistent severe neurological abnormalities at the time of discharge comparable to the rate of neurological sequelae described in children [20] .
While hospital stay for E. coli O157:H7-associated HUS in the USA and UK was 6-14 days, our median length of hospital stay was 3 weeks. Factors like the difference in health-care system, age of the patients and virulence of the strain could have affected this variable [21, 22] .
Overall survival
Mortality reported by the RKI was 53 (6.1%) out of 855 patients with confirmed HUS. The cohort of the STEC-HUS registry had presented a mortality rate of 4.4% which is in line with the 1-5% described in the literature from the 1970s to 1990s [23, 24] . Therefore, short-term mortality during this outbreak was comparable to outbreaks caused by other serotypes [7, [21] [22] [23] [24] [25] .
Comparison of survivors with non-survivors
Age was the most apparent factor discriminating patients who died from those who survived. There were no statistically significant differences in gender distribution, clinical or laboratory baseline parameters. This is in line with previous studies where age was associated with higher mortality. In a nursing home population, the mortality rate among the patients that had a mean age of 83 years was 92% [16] . During the Lancashire outbreak, the average mortality rate was 45%; yet, 7 of 12 deaths occurred in patients over 70 years.
It is of note that limitation of treatment and iatrogenic complication accounted for 9 out of 20 deaths (45%) in our cohort. Withdrawal or limitation of care in HUS patients had already been reported. In the intermountain HUS patient registry , 2 out of 17 deaths (12%) were attributed to treatment limitations [26] . The same holds true for iatrogenic complications which caused 1 out of 17 deaths (6%) of all deaths [26] . Due to the anonymous documentation in our registry, reports of iatrogenic complications might be more frequent. As an objective adverse event, the bleeding complication reported that in an international TPE registry, the rate was 0.5% [27] , which is comparable to the 0.9% bleeding complications in the TPE (and TPE-Ecu)-treated patients and is even lower than the rate of 1.8% severe bleeding complication in the BSC group.
Best supportive care
The prognosis of HUS has improved over the last decades mainly due to the improvements in supportive therapy, consisting of but not limited to control of hypertension, treatment of anaemia, monitoring and aggressive management of fluid status/capillary leakage, mechanical ventilation and dialysis therapy. Early recognition of the infection and parenteral volume expansion has been shown to be associated with attenuated renal injury and failure in a single-centre study [24] . In children, the outcome of HUS patients treated with BSC was comparable to TPE/plasma infusion [24] . During the current outbreak, BSC included therapies such as dialysis (21%) and mechanical ventilation (14%). The higher mortality in the BSC group is mainly due to advanced age and the higher refusal rate of invasive therapy, as discussed above. Two out of six (33%) of patients in the BSC group had advanced directives, limiting treatment options. Moreover, BSC was not always an active treatment decision. This is illustrated by one patient in whom an attempt to place a dialysis catheter for TPE was undertaken but failed causing serious bleeding complications leading to the death of this patient. In an intent-to-treat analysis, this patient would have been in the TPE group but not in the BSC group.
Based on the ad hoc recommendations of the German Society of Nephrology, BSC alone was not encouraged for severe cases of HUS. However, the rational for using BSC alone would be much clearer than for TPE with or without Ecu as BSC has been shown to be effective and results in favourable clinical outcome in children [28] . This is further supported by the analysis of the paediatric patients during the 2011 outbreak. In the recent analysis the majority of the 90 STEC-HUS patients received BSC and presented comparable morbidity and outcome to previous series [29] .
Therapeutic plasma exchange
While TPE has been recommended by the Apheresis Guidelines for the treatment of atypical HUS [30] , the data on TPE for the treatment of STEC-HUS are considerably weaker [8, 31] . Nonetheless, the 2010 guidelines of the American Society for Apheresis list TPE among the recommended treatments for STEC-HUS [30] . Based on these guidelines and on the background of the lifethreatening clinical course of a large number of patients, the DGfN recommended TPE for the current outbreak. We propose that improvement in general medical care rather than the frequent and early use of TPE as recently suggested [32] is a potential explanation of the better outcome in comparison to historic controls.
Eculizumab
The inhibition of terminal complement complex formation by the monoclonal C5 antibody Ecu had been reported as a treatment for atypical HUS in 2009 [33] . On 25 May 2011, Lapeyraque et al. [34] published a letter on Since patients receiving Ecu were more severely ill compared with the patients receiving TPE or BSC alone, a direct comparison of the three treatment groups was not possible. To account for the difference in baseline parameters ( patient's weight, grade of neurologic disorder, need for dialysis), a propensity score-based analysis was performed. Considering the limitations of this approach, univariate as well as multivariate adjustment resulting in balanced baseline parameters did not significantly affect overall survival between the TPE and TPE-Ecu groups.
What could have contributed to the lack of a marked short-term effect of Ecu? First, the complement system might not or not anymore have played the key role in STEC-HUS by the time Ecu was administered. Although the activation of the complement system due to Shigatoxin has been shown in vitro [35] as well as in vivo [36, 37] , the time course of this phenomenon is not fully understood. Evidence points towards the possibility that complement activation after STEC infection can be resolved within a week [37] . This could indicate that the additional Ecu treatment was too late to be effective. Also the effects of Ecu might have been diminished due to the delivery of complement components by fresh frozen plasma [38, 39] as well as by additional complement activation during the TPE procedure itself [40] . The possible effect of Ecu on the long-term outcome remains to be investigated.
Limitations of the study
In a crisis situation, a prospective randomized trial is an uneasy task, and physicians and regulatory agencies were not prepared for. As suggested in 1999 by Dundas et al. [8] , our registry, funded by a professional non-profit organization (DGfN), was an immediate effort to collect observational data during this crisis. Most of the data collection was performed in a prospective manner by personnel directly involved in the diagnosis and treatment of the HUS patients. By the unique means of an online registry, the so far largest data set of a single STEC-HUS outbreak could be accumulated.
Nevertheless, there are inherent limitations of a registry data collection: first of all, assignment to treatment groups was not on an intention-to-treat basis. Data points had to be limited making time course analysis impossible and potentially missing out important data or clinical coordinates. Also data were not documented based on chart review by an independent third party but by the treating physician, with the concomitant risk for reporting bias, especially for 'soft' neurological symptoms such as headache and confusion. Further data analysis is limited to the duration of the hospital stay, making it impossible to detect possible treatment effects beyond the time of hospital discharge.
Moreover, the definition of STEC-HUS was made according to the RKI criteria which only required two out of three criteria (acute kidney injury, haemolytic anaemia and thrombocytopenia) to make the diagnosis of (incomplete) STEC-HUS. Given the high prevalence of neurological symptoms (viewed as microangiopathy) that were not part of the diagnostic criteria of STEC-HUS and not taken into account for the diagnosis of STEC-HUS in our cohort, the current criteria will be open for discussion in the future.
Last but not least, these data cannot provide a solid base for providing or withholding any of the discussed treatments but are meant to serve as foundation of an ongoing discussion above and beyond the role of TPE in STEC-HUS [28, 41, 42] .
Summary
During the 2011 outbreak of E. coli O104:H4 yielding a high percentage of severe HUS, a randomized prospective controlled trial could not be established. Instead, data from an immediately established online Registry under the auspice of the Germany Society of Nephrology were initiated. The observational data of this registry indicate that STEC-HUS is an acute disease with a high percentage of patients suffering from neurological symptoms and renal impairment. Patients frequently require dialysis and ventilator support; yet, overall short-term outcome in adults was better than previously reported. The data from the registry do not support the notion that Ecu in comparison to TPE offers a marked short-term benefit in the treatment of STEC-HUS over TPE alone. Hence, a prospective randomized trial protocol is needed to compare TPE (early use of ) Ecu and BSC in future STEC outbreaks and prior to establishing new treatment algorithms.
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